[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Guo HY, Zhao XM, Cao JN, Hu XC, Yin JL, Hong XN, Li J: [Prognosis of primary non-Hodgkin's lymphoma of the breast]. Zhonghua Zhong Liu Za Zhi; 2008 Mar;30(3):200-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of primary non-Hodgkin's lymphoma of the breast].
  • OBJECTIVE: To analyze the clinical characteristics and prognosis of primary non-Hodgkin's lymphoma of the breast (PNHLB).
  • RESULTS: Of these 45 patients, 37 patients had diffuse large B cell lymphoma (DLBCL), patients with T cell or mucosa-associated lymphoid tissue (MALT) lymphoma were 4, respectively.
  • Most pathologic type was DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Breast Neoplasms, Male / drug therapy. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiotherapy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756936.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Briggs JH, Algan O, Stea B: Primary T-cell lymphoma of the breast: a case report. Cancer Invest; 2003;21(1):68-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary T-cell lymphoma of the breast: a case report.
  • Primary nonHodgkin's lymphoma (NHL) occurs in both nodal and extranodal sites.
  • Lymphoma arising in mammary tissue is rare.
  • The majority are of B-cell origin, while a few case studies of T-cell lymphomas of the breast have been reported.
  • The clinical and histologic features of a 74-year-old female diagnosed with T-cell mammary lymphoma are reported, as well as her treatment course and follow-up.
  • We conclude primary low-grade T cell lymphoma of the breast can be treated with conservative surgery followed by involved field radiation therapy.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Immunophenotyping. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / radiotherapy. Mastectomy, Segmental. Radiotherapy, High-Energy. Remission Induction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12643011.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med; 2002 May;43(5):693-713
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basic problems concerning the choice of antibody and radionuclide and the physiology of tumor and host are discussed.
  • RAIT appears to be gaining a place in the therapy of hematopoietic neoplasms, such as non-Hodgkin's lymphoma, with several agents advancing in clinical trials toward registration, of which one has just been approved by the FDA.
  • [MeSH-minor] Brain Neoplasms / radiotherapy. Breast Neoplasms / radiotherapy. Colorectal Neoplasms / radiotherapy. Female. Hodgkin Disease / radiotherapy. Humans. Leukemia, Myeloid / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, T-Cell / radiotherapy. Male. Ovarian Neoplasms / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy Dosage

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11994535.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA39841; United States / NCI NIH HHS / CA / P01 CA79857
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 205
  •  go-up   go-down


Advertisement
4. Takagi T, Saotome T: Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma; 2001 Aug;42(4):577-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
  • Irinotecan hydrochloride (CPT-11), a DNA topoisomerase-I inhibitor, is now widely used in the treatment of various solid tumors, including colorectal, gastric, breast, lung, and ovarian cancer.
  • Despite the good response shown in the late phase-II study, CPT-11 was not often employed in the treatment of malignant lymphoma, mainly because of severe leukopenia and diarrhea caused by the recommended schedule: 40 mg/m2 of CPT-11 on days 1 to 3, 8 to 10, 15 to 17, then discontinued for at least 2 weeks.
  • Our phase II trial employing a reduced dose of CPT-11 on days 1 and 2, plus ADM on day 3 with 3-week interval in patients with refractory and relapsed NHL showed a fairly good response of relapsed B-cell lymphoma and a substantial response of T-cell lymphoma with acceptable toxicity.
  • Another phase II trial in combination with CPT-11 and other anti-cancer drugs, particularly cisplatin or topoisomerase-II inhibitors, is warranted.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697485.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 42
  •  go-up   go-down


5. Jantunen E, Itälä M, Siitonen T, Koivunen E, Leppä S, Juvonen E, Kuittinen O, Lehtinen T, Koistinen P, Nyman H, Nousiainen T, Volin L, Remes K: Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003. Eur J Haematol; 2006 Aug;77(2):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003.
  • Data on the incidence and causes of late (>100 d) non-relapse mortality (NRM) in autologous stem cell transplant (ASCT) recipients is limited.
  • The most common diagnoses included non-Hodgkin's lymphoma (NHL) (n = 542), multiple myeloma (MM) (n = 528), breast cancer (n = 132); Hodgkin's lymphoma (HL) (n = 86) and chronic lymphocytic leukaemia (CLL) (n = 63).
  • Late NRM was observed in 68 patients (4.6% of ASCT recipients; 11% of all deaths).
  • Twelve patients (0.8% of ASCT recipients) have died due to secondary haematological malignancy.
  • These facts point out the importance of prolonged follow-up in ASCT recipients.
  • [MeSH-major] Neoplasms / surgery. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Postoperative Complications / mortality
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Cardiovascular Diseases / mortality. Cause of Death. Cohort Studies. Combined Modality Therapy. Female. Finland / epidemiology. Follow-Up Studies. Hodgkin Disease / drug therapy. Hodgkin Disease / surgery. Humans. Infection / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / surgery. Neoplasms, Second Primary / mortality. Transplantation Conditioning / mortality. Transplantation, Autologous / mortality. Transplantation, Autologous / statistics & numerical data. Whole-Body Irradiation / adverse effects

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856906.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


6. Ruan J, Hajjar K, Rafii S, Leonard JP: Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol; 2009 Mar;20(3):413-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.
  • While many aspects of postnatal pathological angiogenesis have been extensively studied in the context of nonhematopoietic neoplasms, the precise role of these processes in lymphoma pathogenesis is under active investigation.
  • Lymphoma growth and progression is potentiated by at least two distinct angiogenic mechanisms: autocrine stimulation of tumor cells via expression of vascular endothelial growth factor (VEGF) and VEGF receptors by lymphoma cells, as well as paracrine influences of proangiogenic tumor microenvironment on both local neovascular transformation and recruitment of circulating bone marrow-derived progenitors.
  • Lymphoma-associated infiltrating host cells including hematopoietic monocytes, T cells and mesenchymal pericytes have increasingly been associated with the pathogenesis and prognosis of lymphoma, in part providing perivascular guidance and support to neoangiogenesis.
  • Collectively, these distinct angiogenic mechanisms appear to be important therapeutic targets in selected non-Hodgkin's lymphoma (NHL) subtypes.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1988 Mar;6(3):425-33 [2450970.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Oncogene. 1994 Mar;9(3):963-9 [8108142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] Eur J Haematol. 1996 Jan-Feb;56(1-2):45-53 [8599993.001]
  • [Cites] EXS. 1997;79:209-32 [9002234.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] J Pathol. 1997 Sep;183(1):44-50 [9370946.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2774-6 [16339405.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1712-9 [16520466.001]
  • [Cites] Nat Med. 2006 May;12(5):557-67 [16648859.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):998-1005 [16840188.001]
  • [Cites] Curr Treat Options Oncol. 2006 Jul;7(4):285-94 [16916489.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8814-21 [16951198.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5165-73 [16951235.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5190-8 [16951238.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5622-31 [17020964.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):965-70 [10070898.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2221-30 [10327068.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):154-61 [15671540.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Nat Med. 2005 Mar;11(3):261-2 [15723071.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Genes Dev. 2005 Sep 1;19(17):2054-65 [16107612.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):211-26 [16169466.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3348-52 [16051743.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):184-91 [16397231.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1608-16 [16249383.001]
  • [Cites] Leukemia. 2002 May;16(5):911-9 [11986954.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37 [12138395.001]
  • [Cites] Nat Med. 2002 Aug;8(8):831-40 [12091877.001]
  • [Cites] Nat Med. 2002 Aug;8(8):841-9 [12091880.001]
  • [Cites] J Pathol. 2002 Aug;197(5):677-83 [12210089.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):795-803 [12360282.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3767-75 [12393646.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):116-21 [16971665.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s [17255293.001]
  • [Cites] Nat Rev Drug Discov. 2007 Jan;6(1):21-2 [17269160.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2565-70 [17110461.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):584-95 [17454603.001]
  • [Cites] Haematologica. 2007 Apr;92(4):469-77 [17488657.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5784-9 [17908969.001]
  • [Cites] Lab Invest. 2008 Jan;88(1):38-47 [17998899.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):440-6 [18086798.001]
  • [Cites] Br J Haematol. 2008 Feb;140(3):313-9 [18217897.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):447-50 [18297520.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3131-6 [18174379.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1649-57 [18347166.001]
  • [Cites] Ann Oncol. 2008 May;19(5):964-9 [18296419.001]
  • [Cites] Cancer. 2008 May 15;112(10):2228-32 [18338745.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] Nature. 2008 Jul 31;454(7204):656-60 [18594512.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):728-35 [19373598.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3181-7 [11050001.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4341-4 [11389057.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62 [11553814.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):427-36 [11821955.001]
  • [Cites] Development. 1998 May;125(9):1591-8 [9521897.001]
  • [Cites] Cell. 1998 Sep 18;94(6):715-25 [9753319.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Cell. 2002 Nov 27;111(5):709-20 [12464182.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4 [12516033.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2899-901 [12530014.001]
  • [Cites] Clin Breast Cancer. 2003 Feb;3(6):421-2 [12636887.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Nat Med. 2003 Jun;9(6):789-95 [12740570.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Nat Med. 2003 Jul;9(7):936-43 [12796773.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1142-51 [14561699.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):277-89 [14585355.001]
  • [Cites] Dev Biol. 2003 Dec 1;264(1):275-88 [14623248.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):314-22 [15057291.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):250-9 [15254283.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2084-6 [15191949.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2269-71 [15166030.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2893-902 [15238424.001]
  • [Cites] Semin Hematol. 1987 Apr;24(2 Suppl 1):8-20 [2438781.001]
  • (PMID = 19088170.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL091517; United States / NHLBI NIH HHS / HL / HL 90895; United States / NHLBI NIH HHS / HL / HL42493; United States / NHLBI NIH HHS / HL / HL46403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 126
  • [Other-IDs] NLM/ PMC2733074
  •  go-up   go-down


7. Perrier L, Sebban C, Philip I, Standaert B, Morelle M, Latour JF, Biron P, Philip T: [Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France]. Rev Epidemiol Sante Publique; 2002 Sep;50(4):393-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France].
  • [Transliterated title] Vers une nécessaire harmonisation des évaluations de coûts en santé
  • METHOD: We assessed total cost of 160 consecutive therapeutic intensification procedures using autologous blood progenitor cell transplantation, 95 for lymphoma and 65 for breast tumor.
  • RESULTS: The average total cost of the therapeutic intensification for patients with lymphoma was 227156 francs (34630 euros), including 60720 francs (9257 euros) for mobilization, 14947 francs (22402 euros) for the treatment period and 19489 francs (2971 euros) for secondary hospitalization.
  • The average total cost for patients with a breast tumor was 199626 francs (30433 euros), including 39269 francs (5987 euros) for mobilization, 14912 francs (22737 euros) for the treatment period, and 11215 francs (1709 euros) for secondary hospitalization.
  • [MeSH-major] Breast Neoplasms / economics. Breast Neoplasms / therapy. Health Care Costs. Lymphoma / economics. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / economics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / economics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Costs and Cost Analysis. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / economics. Hodgkin Disease / radiotherapy. Hodgkin Disease / therapy. Hospitalization / economics. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / economics. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Radiotherapy / economics. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12442056.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


8. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A: Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res; 2002 Sep;8(9):2766-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.
  • EXPERIMENTAL DESIGN: Fifteen patients presenting with lung cancer (n = 10), lymphoma (n = 3), or breast cancer (n = 2) underwent (99m)Tc-Annexin V scintigraphy before and within 3 days after their first course of chemotherapy.
  • Despite the lack of tracer uptake after treatment, the 2 patients with breast cancer had a partial response.
  • Initial data suggest that early (99m)Tc-Annexin V tumor uptake may be a predictor of response to treatment in-patients with late stage lung cancer and lymphoma.
  • [MeSH-major] Annexin A5. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Small Cell / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Organotechnetium Compounds. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2002 Sep;8(9):2757-8 [12231512.001]
  • (PMID = 12231515.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m annexin V; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Lu Y, Hou SX, Chen T: [Advances in the study of vincristine: an anticancer ingredient from Catharanthus roseus]. Zhongguo Zhong Yao Za Zhi; 2003 Nov;28(11):1006-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is effective to treat acute lymphocytic cell leukemia, Hodgkin disease and non-Hodgkin disease clinically.
  • In this paper, we summarize physical, chemical, pharmacological and pharmacokinetical properties of VCR and advances in decreasing its side effects.
  • In clinic, association with other medication is adopted.
  • [MeSH-major] Antineoplastic Agents, Phytogenic. Catharanthus. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vincristine
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Humans. Liposomes. Liver Neoplasms / drug therapy. Plants, Medicinal / chemistry. Stomach Neoplasms / drug therapy

  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15615402.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Liposomes; 5J49Q6B70F / Vincristine
  • [Number-of-references] 28
  •  go-up   go-down


10. Protheroe AS, Pickard C, Johnson PW, Craddock T, Shefta J, Short K, Lancaster F, Selby PJ, Henwood J, Boylston AW: Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. Br J Haematol; 2000 Dec;111(3):766-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue.
  • Analysing the regeneration of T lymphocytes after high-dose chemotherapy with autologous peripheral blood progenitor cell rescue (PBPCR) may help elucidate the mechanisms of immune recovery.
  • The T-cell receptor variable beta chain (TCRBV) repertoire of adult patients undergoing high-dose chemotherapy was analysed by flow cytometry, before and after treatment.
  • We demonstrated that, in these patients, following high-dose chemotherapy and autologous stem cell transplantation, the clonal expansions reappeared in peripheral blood and returned to pretransplant levels.
  • They also regenerate T-cell repertoires with each TCRBV family represented to a similar level as that prior to high-dose chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Bone Marrow Purging. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Hematopoietic Stem Cell Transplantation. T-Lymphocytes / immunology
  • [MeSH-minor] Amino Acid Sequence. Breast Neoplasms / immunology. Breast Neoplasms / surgery. Carcinoma, Small Cell / immunology. Carcinoma, Small Cell / surgery. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Drug Administration Schedule. Female. Flow Cytometry. Fluorescent Antibody Technique, Direct. Germinoma / immunology. Germinoma / surgery. Humans. Lung Neoplasms / immunology. Lung Neoplasms / surgery. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / surgery. Male. Melanoma / immunology. Melanoma / surgery. Middle Aged. Molecular Sequence Data. Multiple Myeloma / immunology. Multiple Myeloma / surgery. Polymerase Chain Reaction / methods. Receptor-CD3 Complex, Antigen, T-Cell / genetics. Transplantation, Autologous

  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11122136.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Receptor-CD3 Complex, Antigen, T-Cell; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine
  •  go-up   go-down


11. Belhocine T, Steinmetz N, Green A, Rigo P: In vivo imaging of chemotherapy-induced apoptosis in human cancers. Ann N Y Acad Sci; 2003 Dec;1010:525-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE: Induction of apoptosis in sensitive tumor cells is the main mechanism of action of chemotherapy agents in human cancers.
  • Also, the assessment of drug-induced apoptosis soon after chemotherapy may be an early predictor of treatment efficacy.
  • PATIENTS AND METHODS: A phase I/II study was prospectively conducted in 15 patients presenting with proven lung cancers (n = 10), breast cancers (n = 2), and lymphomas (n = 3) to assess the value of the (99m)Tc-radiolabeled recombinant human (rh) Annexin V for imaging apoptosis immediately after completion of the first course of chemotherapy.
  • RESULTS: All lung and lymphoma patients with an increased tracer uptake post-treatment (n = 8) had either partial or complete tumor response.
  • However, two breast cancers had a response to treatment, although no significant tracer uptake was observed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Annexin A5 / analysis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15033784.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antineoplastic Agents
  •  go-up   go-down


12. Wasil T, Lichtman SM: Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist; 2005 Sep;10(8):602-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly.
  • The adjuvant treatment of breast and colon cancer, as well as the primary therapy of aggressive non-Hodgkin lymphoma is reviewed.
  • The treatment of more advanced breast, ovarian, and non-small cell lung cancer is also discussed.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177284.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 149
  •  go-up   go-down


13. Zhu DM, Uckun FM: Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. Clin Cancer Res; 2000 Jun;6(6):2456-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells.
  • Calpain is a calcium-dependent cysteine protease that is implicated in calcium-dependent cell death, and calpain inhibitors are generally considered as inhibitors of apoptosis.
  • To the contrary, in the present study, we found that calpain inhibitor II (CPI-2) triggers rapid apoptosis in acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) cells.
  • All target cell lines were killed by CPI-2, including: ALL-1, a multidrug-resistant BCR-ABL fusion transcript-positive t(9;22) pro-B ALL cell line; RS4;11, a highly radiation-resistant MLL-AF4 fusion transcript-positive t(4;11) pre-pre B ALL cell line; RAMOS, a highly radiation-resistant and p53-deficient Burkitt's lymphoma cell line; DAUDI, a Burkitt's leukemia/lymphoma cell line; NALM-6, a pre-B ALL cell line; and JURKAT and MOLT-3, two T-lineage ALL/NHL cell lines.
  • CPI-2-induced apoptosis in LYN-deficient and BTK-deficient subclones of the DT-40 lymphoma B cell line as effectively as it did in wild-type DT-40 cells.
  • Unlike the high calpain-expressing ALL/NHL cell lines, myeloid leukemia cell lines HL-60/AML, K562/CML, and U937/AMML, or solid tumor cell lines BT-20/breast cancer, PC-3/prostate cancer, U373/glioblastoma, and HeLa/epitheloid cancer, were not susceptible to the cytotoxicity of CPI-2.
  • CPI-2 and its analogues represent a promising new class of antileukemia/lymphoma agents that deserves further development.
  • [MeSH-major] Apoptosis. Caspases / metabolism. Lymphoma, Non-Hodgkin / metabolism. Oligopeptides / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Cell Separation. DNA / metabolism. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Flow Cytometry. Fluorescein-5-isothiocyanate / metabolism. HL-60 Cells. HeLa Cells. Humans. Immunoglobulin G / metabolism. In Situ Nick-End Labeling. Jurkat Cells. K562 Cells. Microscopy, Confocal. Protein-Tyrosine Kinases / metabolism. Time Factors. Tumor Cells, Cultured. U937 Cells. src-Family Kinases / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10873099.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Oligopeptides; 110115-07-6 / N-acetylleucyl-leucyl-methioninal; 9007-49-2 / DNA; EC 2.7.10.1 / Agammaglobulinaemia tyrosine kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / lyn protein-tyrosine kinase; EC 2.7.10.2 / src-Family Kinases; EC 3.4.22.- / Caspases; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


14. Syme RM, Duggan P, Stewart D, Glück S: Generation of dendritic cells ex vivo: differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors. J Hematother Stem Cell Res; 2001 Oct;10(5):621-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation of dendritic cells ex vivo: differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors.
  • Dendritic cells (DC) are potent antigen-presenting cells that are integral to the initiation of T cell immunity.
  • We examined the optimal time for generating DC and compared DC generated from normal donors for allogeneic blood stem cell transplantation, or patient's with non-Hodgkin's lymphoma or breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation.
  • Blood was obtained from consenting patients prior to granulocyte colony-stimulating factor (G-CSF) administration with (non-Hodgkin lymphoma and breast cancer) or without (normal donors) chemotherapy.
  • A sample of apheresis product (AP) was obtained at the time of apheresis.
  • All cell populations yielded highly pure DC, as assessed by light microscopy and flow cytometry.
  • DC from breast cancer patients functioned significantly better than DC from lymphoma patients in a mixed lymphocyte reaction.
  • [MeSH-major] Dendritic Cells / drug effects. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Interleukin-4 / pharmacology
  • [MeSH-minor] Adult. Aged. Antigens, CD14 / immunology. Antigens, CD34 / immunology. Breast Neoplasms / blood. Cell Count. Female. Hematopoietic Stem Cell Mobilization. Humans. Leukapheresis. Leukocytes, Mononuclear / cytology. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology. Lymphoma / blood. Male. Microscopy, Electron. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11672508.001).
  • [ISSN] 1525-8165
  • [Journal-full-title] Journal of hematotherapy & stem cell research
  • [ISO-abbreviation] J. Hematother. Stem Cell Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antigens, CD34; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


15. Carver JR, Nasta S, Chong EA, Stonecypher M, Wheeler JE, Ahmadi T, Schuster SJ: Myocarditis during lenalidomide therapy. Ann Pharmacother; 2010 Nov;44(11):1840-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report the first case of pathologically confirmed myocarditis in a patient receiving treatment with lenalidomide for non-Hodgkin's lymphoma.
  • CASE SUMMARY: An 85-year-old woman with recurrent follicular lymphoma was treated with lenalidomide 10 mg daily and low-dose dexamethasone 8 mg once weekly in a clinical trial.
  • She had a past medical history of hypertension and breast cancer.
  • DISCUSSION: Lenalidomide is an immunomodulatory agent derived from thalidomide and is approved for the treatment of multiple myeloma and myelodysplastic syndromes.
  • The efficacy of lenalidomide has been reported in B-cell malignancies.
  • We propose an immunological mechanism for myocarditis based on the predominantly T-cell infiltration of the myocardium.
  • CONCLUSIONS: Our findings suggest that lenalidomide may be a cause of drug-induced myocarditis.
  • A reasonable management approach is drug discontinuation and early institution of corticosteroid therapy.
  • An objective causality assessment, using the Naranjo probability scale, revealed that the adverse drug event was probable.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Myocarditis / chemically induced. Thalidomide / analogs & derivatives
  • [MeSH-minor] Aged, 80 and over. Autopsy. Dexamethasone / therapeutic use. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Multiple Organ Failure / etiology. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Myocarditis.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876827.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


16. Dennie TW, Kolesar JM: Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther; 2009;31 Pt 2:2290-311
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
  • Bendamustine was approved by the US Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) in March 2008 and for the treatment of rituximab-refractory, indolent B-cell non-Hodgkin lymphoma (NHL) in October 2008.
  • OBJECTIVE: This article reviews the pharmacologic and pharmacodynamic properties of bendamustine, together with data on efficacy and toxicity from trials investigating the use of bendamustine for the treatment of various hematologic malignancies, including CLL, NHL, and multiple myeloma (MM).
  • METHODS: MEDLINE and International Pharmaceutical Abstracts (1970-April 15, 2009) were searched using the terms bendamustine, bendamustin, Treanda, Ribomustin, SDX-105, IMET-3393, and Cytostasan.
  • RESULTS: Bendamustine is a mechlorethamine derivative with structural similarity to chlorambucil and other drugs from the nitrogen mustard class, as well as a benzimidazole ring, which may act as an antagonist to purines and amino acids.
  • While bendamustine has 2 moieties with possible antitumor effect, it is unclear to what extent the benzimidazole ring enhances the efficacy of the drug.
  • Numerous studies including in vitro assays have reported, however, that bendamustine has little cross-resistance with other alkylating agents and remains active even in extensively pretreated patients.
  • FDA approval for use in CLL was based on findings from a randomized, open-label, Phase III study comparing bendamustine with chlorambucil as single-agent therapy in treatmentnaive patients with CLL (Binet stage B or C).
  • FDA approval for rituximabrefractory, indolent B-cell NHL followed a Phase III, open-label, single-arm study evaluating bendamustine monotherapy in patients who did not respond to rituximab or had progressive disease within 6 months of rituximab therapy.
  • The efficacy of bendamustine has also been reported in the treatment of MM in clinical studies, and bendamustine has been approved in Europe for treating MM, NHL, CLL, breast cancer, and Hodgkin lymphoma.
  • It has been approved in the United States for the treatment of CLL and rituximab-refractory, indolent B-cell NHL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell / drug therapy. Nitrogen Mustard Compounds / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Bendamustine Hydrochloride. Drug Administration Schedule. Drug Resistance, Neoplasm / drug effects. Humans. Rituximab


17. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T: Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol; 2000 Dec;111(4):1122-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Severe hepatic veno-occlusive disease (VOD) is a recognized complication of autologous and allogeneic stem cell transplantation (SCT) that is often fatal.
  • [MeSH-major] Fibrinolytic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Hepatic Veno-Occlusive Disease / drug therapy. Polydeoxyribonucleotides / therapeutic use. Postoperative Complications / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Bilirubin / analysis. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Child. Child, Preschool. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / surgery. Humans. Infant. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / surgery. Male. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11167751.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Polydeoxyribonucleotides; 438HCF2X0M / defibrotide; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down






Advertisement